Area of interest: Biotech
-
Gesynta Pharma raises 26.5 MEUR
(Stockholm, is developing a drug candidate for the treatment of endometriosis): Has raised 26.5 MEUR in a funding round led by Innovestor Life Science, with participation from Hadean Ventures, Linc, Foreground Capital, Catalyze Capital, Stephen Industries, Amboy Street Ventures, and Industrifonden with member Peter Wolpert. The funding will support a Phase II clinical trial in Europe.
-
Cellevate raises 3.2 MEUR
(Lund, develops the next generation of cell culture systems designed to revolutionize biomanufacturing): Has raised 3.2 MEUR in a funding round from the EIC and Industrifonden with member Peter Wolpert. “This renewed investment is dedicated to achieving the most important milestone for Cellevate: the successful global launch, commercialization, and sales of the first nanofiber-based microcarriers in upstream bioprocessing,” comments Laura Chirica.
-
Amferia raises 1.2 MEUR
(Gothenburg, medical devices that kill bacteria, even resistant bacteria, without harming the body): Has raised 1.2 MEUR in a funding round from new and existing investors, including member Björn Engström. “Antibiotics are absolutely essential. Without them, we cannot survive. Our technology is not about replacing antibiotics but helping healthcare professionals use them more effectively,” comments Anand Rajasekharan,…
-
Agteria Biotech raises 16 MSEK
(Stockholm, a novel patent-pending molecule with a 70% efficiency in reducing methane from burping and farting cows): Has raised 16 MSEK in a funding round from Norrsken Launcher with members Erik Engellau-Nilsson, Fredrik Jung Abbou and founding member Ash Pournouri alongside Mudcake with member Anna Nordell Westling and founding member Erik Byrenius. “In my seven years at Norrsken, I have not seen a single case that…
-
Asgard Therapeutics raises 30 MEUR
(Lund, direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies): Has raised 30 MEUR in a funding round from Novo Nordisk, JJDC, RV Invest and Industrifonden with member Peter Wolpert. “Asgard’s technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly inside the patient’s body, comments Cristiana Pires, CEO of Asgard Therapeutics.
-
Pixelgen Technologies raises 7.3 MUSD
(Stockholm, develops tools for the mapping of cell surface proteins and their spatial inter-relationships): Has raised 7.3 MUSD in a funding round from Navigare Ventures and Industrifonden with member Peter Wolpert. “As we enter this next phase of growth, we are grateful and honored to have the support and expertise of Industrifonden and Navigare Ventures and look forward to their contributions,” comments Simon…
-
Cellevate raises 39 MSEK
(Lund, develops the next generation of cell culture systems designed to revolutionize biomanufacturing): Has raised 39 MSEK in a funding round from Onsight Ventures, the EIC with founding member Nicklas Bergmanon the investment board and Industrifonden with member Peter Wolpert. “We look forward to a long-term partnership with Cellevate as they advance their mission of driving innovation in biomanufacturing,” comments Mala Valroy, Investment Manager Industrifonden.
-
Adsorbi raises 4.2 MSEK
(Gothenburg, a novel biomaterial efficient at capturing air pollutants): Has raised 4.2 MSEK in a funding round from Metsä Spring, Jovitech Invest and Chalmers Ventures with member Sara Wallin. Adsorbi aims to help industries in the sustainable transition using a super-material based on cellulose. The material is an adsorbent that is 5-8 times more efficient…
